

Fabio Petrocca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11087896/publications.pdf>

Version: 2024-02-01

19
papers

13,086
citations

430874

18
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

16619
citing authors

#	ARTICLE	IF	CITATIONS
1	A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2257-2261.	7.1	5,220
2	MicroRNA Signatures in Human Ovarian Cancer. Cancer Research, 2007, 67, 8699-8707.	0.9	1,356
3	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 380, 1726-1737.	27.0	1,130
4	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 2021, 384, 705-716.	27.0	1,129
5	MicroRNA Expression Patterns to Differentiate Pancreatic Adenocarcinoma From Normal Pancreas and Chronic Pancreatitis. JAMA - Journal of the American Medical Association, 2007, 297, 1901.	7.4	1,046
6	E2F1-Regulated MicroRNAs Impair TGF β -Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer. Cancer Cell, 2008, 13, 272-286.	16.8	818
7	Genomic Profiling of MicroRNA and Messenger RNA Reveals Deregulated MicroRNA Expression in Prostate Cancer. Cancer Research, 2008, 68, 6162-6170.	0.9	661
8	MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocrine-Related Cancer, 2007, 14, 791-798.	3.1	383
9	Emerging Role of <i>miR-106b-25/miR-17-92</i> Clusters in the Control of Transforming Growth Factor β Signaling. Cancer Research, 2008, 68, 8191-8194.	0.9	369
10	miR-200 Enhances Mouse Breast Cancer Cell Colonization to Form Distant Metastases. PLoS ONE, 2009, 4, e7181.	2.5	282
11	Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nature Communications, 2021, 12, 868.	12.8	173
12	A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells. Cancer Cell, 2013, 24, 182-196.	16.8	147
13	Promise and Challenge of RNA Interference-Based Therapy for Cancer. Journal of Clinical Oncology, 2011, 29, 747-754.	1.6	119
14	Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells. Molecular Cancer Therapeutics, 2015, 14, 2279-2291.	4.1	66
15	Micro-RNAs in Gastrointestinal and Liver Disease. Gastroenterology, 2008, 135, 1866-1869.	1.3	48
16	Alterations of the Tumor Suppressor Gene ARLTS1 in Ovarian Cancer. Cancer Research, 2006, 66, 10287-10291.	0.9	47
17	Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival. Molecular Cancer Therapeutics, 2017, 16, 2849-2861.	4.1	41
18	Micromanipulating cancer: microRNA-based therapeutics?. RNA Biology, 2009, 6, 335-340.	3.1	37

#	ARTICLE	IF	CITATIONS
19	Chapter 4 Micromanagers of Immune Cell Fate and Function. <i>Advances in Immunology</i> , 2009, 102, 227-244.	2.2	14